Drug intelligence / Profile preview

Celecaine

Development stage: Unknown
Lead developer: IHS Bioceuticals
Modality: Small Molecules
Administration: Topical, Oral

Overview

Celecaine is an over-the-counter (OTC) product developed by IHS Bioceuticals, LLC, available in both topical cream and oral capsule formulations. Its active ingredient is a proprietary blend of cetylated fatty acids, which are intended to serve as an alternative to non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors for the management of joint-related conditions. The topical cream is indicated for the temporary relief of minor aches and pains associated with arthritis, simple backache, strains, bruises, and sprains, while the capsules are marketed to promote joint flexibility, mobility, and overall joint health. Although positioned for osteoarthritis treatment, the trademark for Celecaine was cancelled in 2012.

Brand names: Celecaine

Beyond the preview

Go deeper on Celecaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celecaine.

Explore the full profile